Literature DB >> 3563419

Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics.

C Edlund, T Bergan, K Josefsson, R Solberg, C E Nord.   

Abstract

10 healthy volunteers received 200 mg norfloxacin orally every 12 h for 7 days. Saliva, throat and faecal specimens were collected days 0, 3, 5, 7, 14 and 21 to study the effect of norfloxacin on the normal microflora. The concentrations of norfloxacin in serum, urine, saliva and faeces were determined by a microbiological method and all samples except faeces were also assayed by high-pressure liquid chromatography (HPLC). The pharmacokinetics of norfloxacin were studied on day 3. The mean peak serum concentration (+/- SD) attained after 0.75-1.0 h was 0.75 +/- 0.15 mg/l measured by HPLC, and the mean terminal serum half-life was 4.2 +/- 0.6 h. The mean cumulative urinary elimination was 29% during 12 h after dosing. There was no significant difference between values obtained by microbiological assay and by HPLC. The saliva concentration was approximately 30% of the serum levels 1.0-1.5 h after administration. No accumulation in faeces was found during the administration period, and mean concentrations were 940 mg/kg. The changes in the oropharyngeal flora were minor and only branhamella were affected. In the colonic flora, the number of enterobacteria was strongly depressed while the anaerobic microflora was only slightly affected. Two weeks after the administration period, both the oropharyngeal and colonic microflora had returned to normal.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3563419     DOI: 10.3109/00365548709032386

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  18 in total

1.  Use of norfloxacin to study colonization ability of Escherichia coli in in vivo and in vitro models of the porcine gut.

Authors:  E M Nielsen; J Schlundt
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  A norfloxacin dose finding study for selective decontamination of the digestive tract in pigs.

Authors:  L A Van der Waaij; O Messerschmidt; D Van der Waaij
Journal:  Epidemiol Infect       Date:  1989-02       Impact factor: 2.451

Review 3.  Effect of quinolones on the human intestinal microflora.

Authors:  C E Nord
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 4.  Effect of quinolones on intestinal ecology.

Authors:  C Edlund; C E Nord
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 5.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Quinolones in the treatment of acute bacterial diarrhoeal diseases.

Authors:  H E Akalin
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.

Authors:  C Dupeyron; N Mangeney; L Sedrati; B Campillo; P Fouet; G Leluan
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 9.  Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit.

Authors:  P D Potgieter; J M Hammond
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 10.  A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.

Authors:  C Edlund; C E Nord
Journal:  Infection       Date:  1988       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.